Immutep Ltd Stock Australian S.E.
Stocks
AU000000PRR9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 75.16M 53.78M 46.39M 43.64M 39.75M 74.75M 5.1B 516M 201M 2.6B 202M 198M 8.61B | P/E 2027 * |
-2.55x | P/E 2028 * | -3.55x |
|---|---|---|---|---|---|
| Enterprise Value | 41.05M 29.37M 25.34M 23.83M 21.71M 40.83M 2.79B 282M 110M 1.42B 110M 108M 4.7B | EV / Sales 2027 * |
20x | EV / Sales 2028 * | 14.5x |
| Free-Float |
96.98% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | +4.55% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 2014-07-08 |
David Fang
DFI | Director of Finance/CFO | - | 2018-02-28 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 2014-07-08 |
Russell Howard
CHM | Chairman | 76 | 2017-11-16 |
Pete Meyers
BRD | Director/Board Member | 57 | 2014-02-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.55% | +4.17% | - | - | 50.66M | |
| +0.21% | -2.69% | +1.19% | +17.32% | 49.81B | |
| +2.09% | -0.71% | +452.73% | +498.77% | 44.06B | |
| -1.09% | -0.41% | +35.40% | +15.17% | 42.99B | |
| -0.26% | -4.71% | +17.19% | +71.67% | 40.88B | |
| -0.48% | -0.84% | +16.25% | +49.80% | 33.11B | |
| -1.06% | +2.87% | - | - | 17.27B | |
| -1.81% | -5.02% | +22.65% | +113.24% | 16.58B | |
| -1.35% | -3.40% | +10.13% | +26.34% | 14.63B | |
| -2.05% | -5.14% | +72.89% | +34.69% | 13.76B | |
| Average | -0.29% | -2.11% | +78.55% | +103.38% | 30.34B | |
| Weighted average by Cap. | -0.50% | -1.88% | +94.97% | +120.43% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2.06M 1.47M 1.27M 1.19M 1.09M 2.05M 140M 14.12M 5.49M 71.04M 5.52M 5.41M 236M | 1.56M 1.11M 961K 904K 823K 1.55M 106M 10.68M 4.16M 53.77M 4.18M 4.09M 178M |
| Net income | -26.64M -19.06M -16.44M -15.47M -14.09M -26.5M -1.81B -183M -71.17M -920M -71.57M -70.01M -3.05B | -32.58M -23.31M -20.11M -18.92M -17.23M -32.41M -2.21B -224M -87.04M -1.13B -87.53M -85.63M -3.73B |
| Net Debt | -34.11M -24.41M -21.05M -19.8M -18.04M -33.93M -2.32B -234M -91.12M -1.18B -91.63M -89.65M -3.91B | -52.61M -37.64M -32.47M -30.54M -27.82M -52.32M -3.57B -361M -141M -1.82B -141M -138M -6.03B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
